Affordable Access

Prospective evaluation of omeprazole treatment in reflux oesophagitis refractory to H2-receptor antagonists.

Authors
  • Koop, H
  • Hotz, J
  • Pommer, G
  • Klein, M
  • Arnold, R
Type
Published Article
Journal
Alimentary pharmacology & therapeutics
Publication Date
Dec 01, 1990
Volume
4
Issue
6
Pages
593–599
Identifiers
PMID: 1983342
Source
Medline
License
Unknown

Abstract

The efficacy of omeprazole therapy (40 mg daily) in H2-blocker refractory severe reflux oesophagitis (Grade II-IV; Savary and Miller classification) was investigated in 61 patients. Mean duration of reflux disease and preceding H2-antagonist treatment were 4.3 years and 15 months, respectively. Healing rates at 4, 8 and 12 weeks were 48%, 80% and 92%, respectively. There was a correlation between severity of oesophagitis and duration of omeprazole therapy necessary for healing. Three patients (5%) required higher dosages than 40 mg for healing. Symptomatic responses paralleled healing. It is concluded that omeprazole is a highly effective drug for severe reflux oesophagitis not responding to H2-blocker treatment and that 40 mg daily is the optimal dose.

Report this publication

Statistics

Seen <100 times